Maxillary sinus floor elevation with bovine bone mineral combined with either autogenous bone or autogenous stem cells: a prospective randomized clinical trial

Abstract

Mesenchymal stem cells seeded on BioOss(®) particles can induce the formation of a sufficient volume of new bone to enable the reliable placement of implants within a time frame comparable with that of applying either solely autogenous bone or a mixture of autogenous bone and BioOss(®). This technique could be an alternative to using autografts.

Maxillary sinus lift with solely autogenous bone compared to a combination of autogenous bone and growth factors or (solely) bone substitutes. A systematic review

“…To reconstruct bony defects, for example, adding mononuclear stem cells derived from a bone marrow aspirate to Bio-Oss 1 has been shown to result in bone forming kinetics comparable to autogenous bone alone, after a healing period of 3-4 months 23,25 . These mononuclear stem cells can differentiate to osteoblasts if they are added to a bony matrix.…”

Repair of segmental long-bone defects by stem cell concentrate augmented scaffolds: a clinical and positron emission tomography - computed tomography analysis

“…They found that HGF-loaded scaffolds promoted mineralisation, angiogenesis, new bone formation and β-TCP absorption [20]. Sauerbier et al [21] and Rickert et al [22] performed randomised controlled clinical trials to investigate formation of new bone in patients with severe atrophy of the maxillary sinus. Patients obtained an augmentation of the sinus from bovine bone material either with BMAC or autologous bone.…”

The role of bone marrow aspirate cells in the management of atrophic mandibular fractures by mini-invasive surgical approach: Single-institution experience

“…In fact, the vast majority of articles published recently in the literature have focused on the use of autologous stem cells in atrophic mandibles to induce and enhance new bone formation to allow implant placement. For instance, Rickert et al (2011), Katagiri et al (2016), Kawai et al (2015), and Yamada et al (2013) have observed and documented the safe use of mesenchymal stem cell (MSC) bone marrow (BM)-derived bone augmentation for dental implants in patients affected by severe alveolar bone atrophy. All of these authors indicated that this minimally invasive bone regeneration technique was a useful and novel option in dental implant treatment of severe bone atrophy, showing good results through MSCs' great osteogenic potential, together with poor donor site morbidity and few inflammatory signs.…”

“…MSCs have the ability to self-renew and present a multilineage potential (Kan et al, 2005). Their plasticity makes them a promising resource for research in cellular therapy of tissue defects, and several authors have demonstrated how autologous stem cells aspirated from BM can enhance bone healing in in vitro and in vivo studies (Kan et al, 2005;Rickert et al, 2011;Watson et al, 2014;Katagiri et al, 2013;Osugi et al, 2012;Inukai et al, 2013;Kawai et al, 2015;Katagiri et al, 2016). In this regard, osteoinductive growth factors such as bone morphogenic protein (BMP)-2 have been already used with osteoconductive materials to promote bone regeneration (Herford and Boyne, 2008).…”